160 related articles for article (PubMed ID: 29293235)
1. The struggle to do no harm in clinical trials.
Schmidt C
Nature; 2017 Dec; 552(7685):S74-S75. PubMed ID: 29293235
[No Abstract] [Full Text] [Related]
2. Making cancer immunotherapy a surer bet.
Eisenstein M
Nature; 2017 Dec; 552(7685):S72-S73. PubMed ID: 29293218
[No Abstract] [Full Text] [Related]
3. [Immunotherapy in lung cancer: checkpoint inhibitors].
Wehler T; Wehler B; Stehle I
Dtsch Med Wochenschr; 2015 Dec; 140(24):1835-8. PubMed ID: 26625234
[TBL] [Abstract][Full Text] [Related]
4. Part I: Checkpoint inhibitors in cancer therapy.
Daud AI
Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535
[No Abstract] [Full Text] [Related]
5. Attack of the killer clones.
Scudellari M
Nature; 2017 Dec; 552(7685):S64-S66. PubMed ID: 29293233
[No Abstract] [Full Text] [Related]
6. Cancer treatment: The killer within.
Ledford H
Nature; 2014 Apr; 508(7494):24-6. PubMed ID: 24695297
[No Abstract] [Full Text] [Related]
7. The immune checkpoint inhibitors: where are we now?
Webster RM
Nat Rev Drug Discov; 2014 Dec; 13(12):883-4. PubMed ID: 25345674
[No Abstract] [Full Text] [Related]
8. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
O'Kane GM; Labbé C; Doherty MK; Young K; Albaba H; Leighl NB
Oncologist; 2017 Jan; 22(1):70-80. PubMed ID: 27534573
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.
Gormley NJ; Pazdur R
N Engl J Med; 2018 Nov; 379(19):1791-1795. PubMed ID: 30403935
[No Abstract] [Full Text] [Related]
10. Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis.
Nader ME; Myers JN; Gidley PW
J Immunother Cancer; 2017; 5():24. PubMed ID: 28331614
[TBL] [Abstract][Full Text] [Related]
11. The double edge of cancer immunotherapy.
Nat Med; 2017 Feb; 23(2):137. PubMed ID: 28170382
[No Abstract] [Full Text] [Related]
12. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
Spain L; Larkin J
Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
[No Abstract] [Full Text] [Related]
13. Cancer immunotherapy: Progress and challenges in the clinical setting.
Zarour HM; Ferrone S
Eur J Immunol; 2011 Jun; 41(6):1510-5. PubMed ID: 21618503
[No Abstract] [Full Text] [Related]
14. Programmed death protein 1 inhibitors making inroads in multiple cancers.
Brower V
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
[No Abstract] [Full Text] [Related]
15. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.
Inno A; Metro G; Bironzo P; Grimaldi AM; Grego E; Di Nunno V; Picasso V; Massari F; Gori S
Tumori; 2017 Sep; 103(5):405-421. PubMed ID: 28497847
[TBL] [Abstract][Full Text] [Related]
17. Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies.
Komaki Y; Komaki F; Yamada A; Micic D; Ido A; Sakuraba A
Clin Pharmacol Ther; 2018 Feb; 103(2):318-331. PubMed ID: 28118483
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry.
Tavares ABMLA; Lima Neto JX; Fulco UL; Albuquerque EL
Sci Rep; 2018 Jan; 8(1):1840. PubMed ID: 29382901
[TBL] [Abstract][Full Text] [Related]
19. TNF blockade and cutaneous lupus erythematosus: where do we stand and where are we going?
Zattra E; Stan R; Russo I; Lo Nigro A; Peserico A; Alaibac M
Immunotherapy; 2013 Aug; 5(8):791-4. PubMed ID: 23902545
[No Abstract] [Full Text] [Related]
20. American Association of Cancer Research Showcases Immunotherapy Advances.
Brower V
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
[No Abstract] [Full Text] [Related]
[Next] [New Search]
